Limits...
Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson's disease.

Pan W, Kwak S, Li G, Chen Y, Cai D - Chin Med (2013)

Bottom Line: A total of 61 (placebo group, n = 30; YXQN group, n = 31) idiopathic PD participants with sleep dysfunction (mean age ± standard deviation, 63.4 ± 8.6 years; mean duration of illness, 5.8 ± 6.6 years) completed the study.Significant improvements in EA (p = 0.033, 0.037 and 0.029), DA (p = 0.041, 0.038 and 0.027) and PDSS score (p = 0.034, 0.028 and 0.029) were observed in the YXQN group at weeks 8 and 12, and maintained until week 16, respectively.YXQN improved the DFA parameters, and PDSS and UPDRS scores in PD participants.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Neurology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 185, Pu-An Road, Shanghai 200021, China ; Department of Neurology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

ABSTRACT

Background: This study aimed to evaluate the effects of add-on Yang-Xue-Qing-Nao granules (YXQN) on sleep dysfunction in patients with Parkinson's disease (PD).

Methods: PD participants fitted with an actigraph took either YXQN or placebo granules in a randomized manner for 12 weeks while maintaining other anti-parkinsonism medications (e.g., dopaminergic agent, dopamine agonist) unchanged. Additional participants without sleep disturbance or PD served as controls. The changes in detrended fluctuation analysis (DFA) of physical activity with respect to diurnal activity (DA), evening activity (EA), nocturnal activity (NA), Parkinson's disease sleep scale (PDSS) score and unified Parkinson's disease rating scale (UPDRS) score were evaluated every 4 weeks during the 12-week YXQN intervention period and again at week 16.

Results: A total of 61 (placebo group, n = 30; YXQN group, n = 31) idiopathic PD participants with sleep dysfunction (mean age ± standard deviation, 63.4 ± 8.6 years; mean duration of illness, 5.8 ± 6.6 years) completed the study. Significant improvements in EA (p = 0.033, 0.037 and 0.029), DA (p = 0.041, 0.038 and 0.027) and PDSS score (p = 0.034, 0.028 and 0.029) were observed in the YXQN group at weeks 8 and 12, and maintained until week 16, respectively.

Conclusion: YXQN improved the DFA parameters, and PDSS and UPDRS scores in PD participants.

No MeSH data available.


Related in: MedlinePlus

Daily profiles of actigraph counts showing the biological rhythm before and after granule ingestion in the control group (A), placebo group (B), and Yang-Xue Qing-Nao granule (YXQN) group (C). The light green color indicates sleep duration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3733743&req=5

Figure 1: Daily profiles of actigraph counts showing the biological rhythm before and after granule ingestion in the control group (A), placebo group (B), and Yang-Xue Qing-Nao granule (YXQN) group (C). The light green color indicates sleep duration.

Mentions: NA was decreased after the additional treatment in the YXQN group (Figure 1B and C). The improvements in NA in the YXQN group after continuous daily treatment for 12 weeks were similar to those in the control group (Figure 1A and C). In both the YXQN group and the placebo group, the α values of DFA for DA, EA and NA, and the PDSS score at baseline were significantly different from those in the control group (Figure 2). The α values of DA in the YXQN group decreased slightly during the 16-week observation period (Figure 2A). The α values for EA in the YXQN group were decreased at weeks 4, 12 and 16 compared with the placebo group (Figure 2B). Compared with the placebo group, the YXQN group had significantly increased α values for NA at weeks 8, 12 and 16, and increased PDSS values (Figure 2C and D). The better UPDRS scores were observed in the YXQN group at the end of the intervention compared with the placebo group, but there were no significant changes compared with baseline in either group of PD participants (Table 2). The improvements in the α values and PDSS score in the YXQN group were similar to those in the control group, and the effects in the YXQN group were maintained for 4 weeks (Figure 2). No serious adverse events were observed.


Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson's disease.

Pan W, Kwak S, Li G, Chen Y, Cai D - Chin Med (2013)

Daily profiles of actigraph counts showing the biological rhythm before and after granule ingestion in the control group (A), placebo group (B), and Yang-Xue Qing-Nao granule (YXQN) group (C). The light green color indicates sleep duration.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3733743&req=5

Figure 1: Daily profiles of actigraph counts showing the biological rhythm before and after granule ingestion in the control group (A), placebo group (B), and Yang-Xue Qing-Nao granule (YXQN) group (C). The light green color indicates sleep duration.
Mentions: NA was decreased after the additional treatment in the YXQN group (Figure 1B and C). The improvements in NA in the YXQN group after continuous daily treatment for 12 weeks were similar to those in the control group (Figure 1A and C). In both the YXQN group and the placebo group, the α values of DFA for DA, EA and NA, and the PDSS score at baseline were significantly different from those in the control group (Figure 2). The α values of DA in the YXQN group decreased slightly during the 16-week observation period (Figure 2A). The α values for EA in the YXQN group were decreased at weeks 4, 12 and 16 compared with the placebo group (Figure 2B). Compared with the placebo group, the YXQN group had significantly increased α values for NA at weeks 8, 12 and 16, and increased PDSS values (Figure 2C and D). The better UPDRS scores were observed in the YXQN group at the end of the intervention compared with the placebo group, but there were no significant changes compared with baseline in either group of PD participants (Table 2). The improvements in the α values and PDSS score in the YXQN group were similar to those in the control group, and the effects in the YXQN group were maintained for 4 weeks (Figure 2). No serious adverse events were observed.

Bottom Line: A total of 61 (placebo group, n = 30; YXQN group, n = 31) idiopathic PD participants with sleep dysfunction (mean age ± standard deviation, 63.4 ± 8.6 years; mean duration of illness, 5.8 ± 6.6 years) completed the study.Significant improvements in EA (p = 0.033, 0.037 and 0.029), DA (p = 0.041, 0.038 and 0.027) and PDSS score (p = 0.034, 0.028 and 0.029) were observed in the YXQN group at weeks 8 and 12, and maintained until week 16, respectively.YXQN improved the DFA parameters, and PDSS and UPDRS scores in PD participants.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Neurology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 185, Pu-An Road, Shanghai 200021, China ; Department of Neurology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

ABSTRACT

Background: This study aimed to evaluate the effects of add-on Yang-Xue-Qing-Nao granules (YXQN) on sleep dysfunction in patients with Parkinson's disease (PD).

Methods: PD participants fitted with an actigraph took either YXQN or placebo granules in a randomized manner for 12 weeks while maintaining other anti-parkinsonism medications (e.g., dopaminergic agent, dopamine agonist) unchanged. Additional participants without sleep disturbance or PD served as controls. The changes in detrended fluctuation analysis (DFA) of physical activity with respect to diurnal activity (DA), evening activity (EA), nocturnal activity (NA), Parkinson's disease sleep scale (PDSS) score and unified Parkinson's disease rating scale (UPDRS) score were evaluated every 4 weeks during the 12-week YXQN intervention period and again at week 16.

Results: A total of 61 (placebo group, n = 30; YXQN group, n = 31) idiopathic PD participants with sleep dysfunction (mean age ± standard deviation, 63.4 ± 8.6 years; mean duration of illness, 5.8 ± 6.6 years) completed the study. Significant improvements in EA (p = 0.033, 0.037 and 0.029), DA (p = 0.041, 0.038 and 0.027) and PDSS score (p = 0.034, 0.028 and 0.029) were observed in the YXQN group at weeks 8 and 12, and maintained until week 16, respectively.

Conclusion: YXQN improved the DFA parameters, and PDSS and UPDRS scores in PD participants.

No MeSH data available.


Related in: MedlinePlus